Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 9

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 9
---
2025, the Company unveiled a new strategic initiative to introduce Nugevia—a consumer-oriented product line dedicated to longevity and wellness. This initiative aims to meet the rising demand for scientifically validated wellness solutions by developing nutritional products that support both longevity and health span. Positioned within a rapidly growing global industry expected to reach $8 trillion by 2030, Nugevia products will leverage Jupiter’s proprietary JOTROL ™technology, a resveratrol-based platform shown to deliver a nine-fold increase in bioavailability.

The first products under the Nugevia brand, focusing on longevity and healthspan are available for sale and shipments are expected in the fourth quarter of 2025 through a direct-to-consumer (“DTC”) model. The products are:

| ● | Nugevia                                                                        
 GLO (“GLO”), which promotes cellular defense and skin vitality from the inside 
 out;                                                                           |
| ● | Nugevia                                                                        
 MND (“MND”), which supports cognitive resilience; and                          |
| ● | Nugevia                                                                        
 PWR (“PWR”), which helps replenish mitochondrial function, which is a key for  
 sustained growth and performance.                                              |

The three debut formulations—GLO, MND, and PWR—are designed to support cellular resilience through intelligent stacking of synergistic ingredients, all enhanced for optimal absorption via the JOTROL ™system.

The Company plans to market these products in the U.S. and internationally.

Nugevia’s launch is a pivotal move to monetize Jupiter’s proprietary science, support ongoing clinical trials, and capture a share of the booming longevity market.

The Company operates through two segments: (i) the sale of premium nutritional supplements under the Nugevia brand, and (ii) pharmaceutical operations centered on the development of drug candidates.

For other information on our business and product details, see “ Description of Business” section.

The Standby Equity Purchase Agreement

On October 24, 2025, Jupiter Neurosciences, Inc. entered into the SEPA and a related Registration Rights Agreement (the “Registration Rights Agreement”), each dated as of October 24, 2025, with Yorkville, pursuant to which the Company has the right to sell to Yorkville up to $20.0 million of its common stock, par value $0.0001 per share, subject to certain limitations and conditions set forth in the SEPA, from time to time during the term of the SEPA. Such shares of common stock registered under this prospectus include (i) up